NEOPHARM INC. - wieder nach Norden? ( Seite 22)

Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm as Chief Development Officer



PHOENIX--(BUSINESS WIRE)-- INSYS Therapeutics/NeoPharm (Other OTC: NEOL.PK) announces the inclusion of Daniel D. Von Hoff, M.D., F.A.C.P. to their management team as Chief Development Officer. Dr. Von Hoff also currently serves as Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare. He holds an appointment as Clinical Professor of Medicine, University of Arizona, College of Medicine.

Dr Von Hoff is the founder of ILEX™ Oncology, Inc. (acquired by Genzyme) as well as founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and Editor-in-Chief of Molecular Cancer Therapeutics. Additionally, he is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He was appointed to President Bush’s National Cancer Advisory Board in 2004-2010, is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.

Dr. Von Hoff is the recipient of the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research. His major interest is in the development of new anticancer agents, both in the clinic and in the laboratory and he has been involved in the beginning of the development of multiple regularly used agents.

Dr Von Hoff states, “It is clear that supportive care including pain control, improving appetite and muscle mass are critical for the survival of patients with cancer. I am very pleased to be working with a team that has such a drive to make a difference in that area of patient care.”

Michael Babich, President and COO of INSYS/NeoPharm, adds, “We are delighted to have someone with the expertise in oncology and supportive care that Dan embodies join our management team. Dan’s vision and ability to bring oncology drugs to the marketplace is unmatched and his addition will strengthen our oncology focus.”

About INSYS Therapeutics, Inc.

INSYS Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. We develop new formulations and delivery methods for existing drugs in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Our drug development programs are based on existing compounds with known or proven safety, efficacy and commercialization histories. We are focused on leveraging our expertise in the expanding synthetic cannabinoid derivatives and specialized opioid markets to build a portfolio of proprietary products that address the limitations of existing therapies.


Source: INSYS Therapeutics/NeoPharm



Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=201101061320bizwire_usprx____bw6658&title=dr-daniel-von-hoff-joins-insys-therapeuticsneopharm-as-chief-development-officer#ixzz1AM0WHAjr

http://en.wikipedia.org/wiki/Daniel_Von_Hoff

ich denke, dass Dr. von Hoff Veopharm zu alter Stärke zurückführen könnte.

Company News
NEOL NEOL
NeoPharm, Inc. Other OTC




Back to Headlines | Print Version | ShareThis



Insys Therapeutics, Inc. Announces Submission of NDA for Fentanyl SL Spray



PHOENIX--(BUSINESS WIRE)-- Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC: NEOL.PK) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for its cancer pain product candidate, Fentanyl SL Spray.

“This is a tremendous achievement for the Company, and evidences our continued dedication to the development of improved products in the supportive care and oncology space,” said Insys CEO Michael Babich. “We are excited for the prospects of Fentanyl SL Spray’s unique delivery system and look forward to building a sales force to launch this product candidate, if approved.”

About Insys Therapeutics, Inc.

Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.

Forward Looking Statements

This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, Insys’ plans to build a sales force, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.



Source: Insys Therapeutics, Inc.




Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=201103071600bizwire_usprx____bw6855&title=insys-therapeutics-inc-announces-submission-of-nda-for-fentanyl-sl-spray#ixzz1G1hIA3Hh

jetzt geht die Party richtig los

schon bei 0,365 USD

in Ffm plus 39,9 % auf 0,27 Euro.

So kann es weitergehen

Neopharm ist in Insys Therapeutics aufgegangen, hat aber in den USA noch das Symbol NEOL.PK behalten.
Ist hier schon jemanden die neue Isin oder WKN bekannt?
Die o.a. Angaben stimmen nicht mehr

Antwort auf Beitrag Nr.: 41.445.147 von Nissie am 03.05.11 15:30:33Neue Isin: US45824V1008
neue WKN A1JGFJ
in den USA gilt weiter das Symbol NEOL